The TruDelivery® RTU portfolio helps meet the real-world challenges of hospital pharmacies — and is always ready when you are. It’s about time.
Company Background
Endo focuses on developing and delivering specialty pharmaceutical products — many of which are complex in nature and require unique expertise, technology, and equipment. We focus on medical therapeutics, specifically in the areas of urology, orthopedics, and endocrinology, and on sterile injectables for hospitals and health systems, along with generics. Our Endo Injectable Solutions business unit works with hospitals and healthcare systems to reduce complexity through operational efficiencies, innovating together to add value where it matters — from manufacturing to treatment — so that healthcare providers can focus on patient care. Our aseptic product portfolio spans various therapeutic categories and includes both branded and generic injectables.
Product Overview
Our RTU products, available through our TruDelivery® platform (TruDelivery.com), streamline hospital operations by eliminating the need for preparation time or transfer before patient administration. This can reduce preparation time, enhance convenience and workflow, and minimize potential preparation errors. All these advantages support quality care for patients in hospitals, clinics, and home health and long-term care systems. TruDelivery® RTU products require no compounding, diluting, or mixing1-5 and provide extended dating compared with compounded products.6-10,11* Most hospital pharmacy buyers can purchase TruDelivery® RTU products with their routine daily wholesale orders. These TruDelivery® RTU products are already available through your health system’s full-line wholesaler and on your group purchasing organization (GPO) contract.
It’s About Time for Simplicity and Efficiency
TruDelivery® RTU products are designed to help address some of the challenges facing hospital pharmacies. Products that require the use of a separately packaged diluent, or that require mixing, compounding, or transferring to another container for administration, all require multiple steps before the medication can be administered to a waiting patient. Even under the best circumstances, extra steps may introduce risk of error.12-16 In the Food and Drug Administration’s (FDA) guidance to medication manufacturers, the agency encourages the manufacture of products specifically designed to minimize medication errors. Reducing the steps required for preparation and administration may help reduce risk of medication errors.15
Explore the Growing Portfolio of TruDelivery® RTU Products
Contact your Endo Key Account Manager for more information on the below TruDelivery® products:
• Bivalirudin Injection RTU Bottles
• Dexmedetomidine Hydrochloride Injection RTU Bottles
• Ephedrine Sulfate Injection RTU Vials
• PREVDUO® (Neostigmine Methylsulfate and Glycopyrrolate) Injection RTU Prefilled Syringes
• Vasostrict® (Vasopressin Injection, USP) RTU Bottles
*For Category 3 compounded sterile preparations (CSP), the maximum beyond-use date (BUD) is 90 days at controlled room temperature (CRT), 120 days in refrigerator, and 180 days in freezer11 versus shelf life of two years at CRT for Dexmedetomidine, Ephedrine, and PREVDUO®7-9; 12 months at CRT and two years in refrigerator for Vasostrict®6; 72 hours at CRT and 18 months in refrigerator for Bivalirudin.5,10
References:
1. Vasostrict®. Prescribing Information. Endo USA, Inc. 2. PREVDUO®. Prescribing Information. Endo USA, Inc. 3. Ephedrine Sulfate Injection. Prescribing Information. Endo USA, Inc. 4. Dexmedetomidine Hydrochloride Injection. Prescribing Information. Endo USA, Inc. 5. Bivalirudin Injection. Prescribing Information. Endo USA, Inc. 6. Data on file. DOF-VS-02. Endo USA, Inc.; September 20, 2023. 7. Data on file. DOF-PRVD-01. Endo USA, Inc.; July 20, 2023. 8. Data on file. DOF-EH-01. Endo USA, Inc.; July 31, 2023. 9. Data on file. DOF-DX-01. Endo USA, Inc.; July 26, 2023. 10. Healthcare Distribution Alliance. Standard pharmaceutical product and medical device information: Bivalirudin Injection. July 10, 2023. 11. The United States Pharmacopeial Convention. USP compounding standards and beyond-use-dates. https://go.usp.org/2022_Revisions_795_797. Accessed April 29, 2024. 12. Fanikos J, Burger M, Canada T, et al. An assessment of currently available i.v. push medication delivery systems. Am J Health-Syst Pharm. 2017;74(9):e230- 235. 13. Institute for Safe Medication Practices. ISMP safe practice guidelines for adult IV push medications. https://www.ismp.org/sites/default/files/attachments/2017-11/ISMP97 Guidelines-071415-3.%20FINAL.pdf. Accessed April 29, 2024. 14. Hertig JB, Degnan DD, Scott CR, Lenz JR, Li X, Anderson CM. A comparison of error rates between intravenous push methods: a prospective, multisite, observational study. J Patient Saf. 2018;14(1):60-65. 15. U.S. Food & Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research. Safety considerations for product design to minimize medication errors: guidance for industry. https://www.fda.gov/media/84903/ download. Published April 2016. Accessed April 29, 2024. 16. American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J HealthSyst Pharm. 2018;75(19):1493-1517.
Learn More: parpharm.com
